COMP <GO>
VCYT vs LLY // RSI-14 & 200D SMA MOMENTUM
Veracyte Inc. (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: VCYT 3
— LLY 11
▲ RSI-14 & 200D SMA MOMENTUM LEADER: LLY
LAST: $50.01 (-4.14%) • MKT CAP: $4.19B
rsi-technicals
60.9
LAST: $1,417.54 (+3.19%) • MKT CAP: $1.33T
rsi-technicals
77.9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (VCYT VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | VCYT | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 70.10% | 83.64% | -13.54 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 4.60% | 32.36% | -27.76 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | 58.7x | 36.4x | +22.28 | LLY | /valuation <GO> |
| Free Cash Flow Yield | 3.02% | 2.30% | +0.72 | VCYT | /fcf-yield <GO> |
| Operating Margin | 11.20% | 40.21% | -29.01 | LLY | /operating-margins <GO> |
| Net Profit Margin | 12.80% | 31.90% | -19.10 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 16.00% | 45.51% | -29.51 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 9.29 | +16.71 | VCYT | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 9/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.20% | 6.77% | +0.43 | LLY | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 60.9 | 77.9 | -16.96 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.08 | 0.51 | +0.57 | VCYT | /macro-sensitivity <GO> |
| Forward P/E Multiple | 53.1x | 26.3x | +26.85 | LLY | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $4.19B | $1.33T | -$1.33T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | VCYT REV | LLY REV | VCYT GROSS % | LLY GROSS % | VCYT FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $517.1M | $65.18B | 70.1% | 83.0% | $126.6M | $16.81B |
| FY 2024 | $445.8M | $45.04B | 66.9% | 81.3% | $63.8M | $8.82B |
| FY 2023 | $361.1M | $34.12B | 44.0% | 79.3% | $28.0M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
VCYT // BETA 1.08
LLY // BETA 0.51